Trials / Completed
CompletedNCT01393756
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma
A Phase Ib/II Study of Escalating Doses of Revlimid in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- The Lymphoma Academic Research Organisation · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular lymphoma as measured by the response rate at the end of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide and R-CHOP | Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2013-07-01
- Completion
- 2015-11-01
- First posted
- 2011-07-13
- Last updated
- 2023-12-05
Locations
24 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01393756. Inclusion in this directory is not an endorsement.